MEDI 8490
Alternative Names: MEDI8490Latest Information Update: 28 Aug 2021
Price :
$50 *
At a glance
- Originator MedImmune
- Developer AstraZeneca
- Class Antidementias; Monoclonal antibodies
- Mechanism of Action Amyloid beta-protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for preclinical development in Alzheimer's-disease in United Kingdom (Intracardiac, Injection)
- 28 Aug 2021 No recent reports of development identified for preclinical development in Alzheimer's-disease in United Kingdom (Intracerebral, Injection)
- 24 Aug 2017 MedImmune has patent protection for MEDI 8490 worldwide